Positron emission tomography-computed tomography on predicting the efficacy of targeted therapy for lung adenocarcinoma
Background: In this study,positron emission tomography-computed tomography ( PET-CT) was used to monitor the maximal standard uptake value ( SUVmax) in advanced lung adenocarcinoma patients with epithermal growth factor receptor ( EGFR) mutation as to prove its role in predicting the prognosis of the targeted therapy.Methods: A total of 46 patients with advanced lung adenocarcinoma ( IIIb - IV stage) were enrolled in the current study.They were positive for EGFR mutation.All patients received gefitinib (250 mg per day,administered orally).PET -CT was conducted prior to (at baseline) and 6 months after gefitinib administration for the lesion size and SUVmax.The recommendations of the E uropean Organization for Research and Treatment of Cancer ( EORTC) criteria were chosen for the PET assessment.Metabolic response ( SUV decline <-25%) was compared with morphologic response evaluated by CT scan and overall survival.Result: Compared to patients with △SUV% ≥ 25% (progressive metabolic disease),the survival time was significantly prolonged in △SUV% < ?25% (including complete metabolic response and progressive metabolic disease) (10.6/18.4,P = 0.000),but was not in ?25% ≤ △SUV% < 25% (stable metabolic disease) (10.6/10.7,P = 0.088).Patients who achieved △SUV%<-25% after treatment were associated with a longer median survival,higher control rate,and better prognosis.There was a strong correlation between SUV changes (△SUV%) and CT size change (△lesion size%) (R2 = 0.891,P = 0.000).Conclusion: Changes in the SUV could be used to predict the prognosis of targeted therapy in advanced lung adenocarcinoma.
Xiaoxiang Rong Rongcheng Luo Xiaoli Cai Rong Li Jinzhang Chen Quanshi Wang Changxuan You Wenyun Wu Chuanxin Liu Junyi Zhang
国内会议
第五届国际中医、中西医结合肿瘤学术交流大会暨第十四届全国中西医结合肿瘤学术大会
广州
英文
1-6
2014-07-01（万方平台首次上网日期，不代表论文的发表时间）